As geopolitical tensions and energy market volatility capture global attention, Asian markets are navigating a complex landscape influenced by these dynamics. In this environment, dividend stocks can offer stability and income potential, making them an attractive consideration for investors seeking to balance risk with consistent returns.
| Name | Dividend Yield | Dividend Rating |
| SIGMAXYZ Holdings (TSE:6088) | 4.51% | ★★★★★★ |
| Sakai Moving ServiceLtd (TSE:9039) | 3.94% | ★★★★★★ |
| NCD (TSE:4783) | 4.85% | ★★★★★★ |
| KSKLtd (TSE:9687) | 4.32% | ★★★★★★ |
| HUAYU Automotive Systems (SHSE:600741) | 6.01% | ★★★★★★ |
| Guangxi LiuYao Group (SHSE:603368) | 4.27% | ★★★★★★ |
| GakkyushaLtd (TSE:9769) | 4.98% | ★★★★★★ |
| Changjiang Publishing & MediaLtd (SHSE:600757) | 5.32% | ★★★★★★ |
| Business Brain Showa-Ota (TSE:9658) | 4.52% | ★★★★★★ |
| Binggrae (KOSE:A005180) | 5.12% | ★★★★★★ |
Click here to see the full list of 1033 stocks from our Top Asian Dividend Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Plan B Media Public Company Limited, along with its subsidiaries, offers advertising media production services in Thailand and has a market cap of ฿26.22 billion.
Operations: Plan B Media Public Company Limited generates revenue from its advertising media segment, which contributes ฿2.39 billion, and its engagement marketing segment, which adds ฿10.24 billion.
Dividend Yield: 3.7%
Plan B Media's dividend payments are well-covered by cash flows, with a cash payout ratio of 31.9%, though its dividend yield of 3.7% is below the top tier in Thailand. Despite recent earnings growth and a fair valuation, the company's dividends have been historically volatile and unreliable over the past decade. Recent investments in COM7 Public Company Limited may impact future financial stability and dividend sustainability, given their significant scale at THB 7.22 billion.
Simply Wall St Dividend Rating: ★★★★★★
Overview: Luyan Pharma Co., Ltd. is involved in the research, development, production, and sale of pharmaceutical products and prepared slices of traditional Chinese medicine in China, with a market capitalization of CN¥4.35 billion.
Operations: Luyan Pharma Co., Ltd. generates revenue through its activities in the research, development, production, and sale of pharmaceutical products and prepared slices of traditional Chinese medicine within China.
Dividend Yield: 3.1%
Luyan Pharma Ltd. offers a reliable dividend yield of 3.13%, ranking in the top 25% of Chinese dividend payers, supported by a manageable payout ratio of 49.3%. The company's dividends have been stable and growing over the past decade, with recent affirmations confirming continued payments. Although its debt coverage by operating cash flow is not optimal, Luyan's price-to-earnings ratio of 15.7x suggests fair valuation compared to the broader market's higher average.
Simply Wall St Dividend Rating: ★★★★☆☆
Overview: Sanko Gosei Ltd. specializes in the molding and sale of plastic products and plastic molding dies both in Japan and internationally, with a market cap of ¥28.17 billion.
Operations: Sanko Gosei Ltd.'s revenue is derived from several regions, including ¥33.11 billion from Asia, ¥36.64 billion from Japan, ¥12.18 billion from Europe, and ¥20.39 billion from North America.
Dividend Yield: 3%
Sanko Gosei's recent guidance indicates a solid financial outlook with expected net sales of ¥105 billion and operating profit of ¥7.9 billion for fiscal 2027. The company plans to increase its dividends to ¥16 per share, up from the previous year's ¥14, reflecting a positive trend despite an unstable dividend history. With a low payout ratio of 20.2%, dividends are well covered by earnings and cash flows, although past volatility raises concerns about long-term reliability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com